BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug

BioAge Labs

06/12/2024 23:04

** Shares of drug developer BioAge Labs  BIOA.O  crater
67.6% to $6.52 in extended trading
    ** Co discontinues mid-stage trial of its experimental
obesity drug after high levels of certain liver enzymes observed
in some patients
    ** BioAge's experimental drug, azelaprag, mimics activity of
the exerkine apelin, a peptide released in response to exercise
due to muscle contraction
    ** Co was studying azelaprag as a monotherapy and in
combination with Eli Lilly's  LLY.N  tirzepatide
    ** BioAge has stopped dosing all patients and plans to
further analyze data from people who have been enrolled
    ** As of last close, stock down ~10% since its market debut
in September

 (Reporting by Juveria Tabassum in Bengaluru)
 ((Juveria.Tabassum@thomsonreuters.com;))